Sex and Gender Differences in Myocarditis and Dilated Cardiomyopathy

Current Problems in Cardiology

Volumn 38, Issue 1, 2013, Pages 7-46

  Fairweather, DeLisa ^a   Cooper, Leslie T ^a   Blauwet, Lori A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BROMOCRIPTINE; CANDESARTAN; CARVEDILOL; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EPLERENONE; ESTRADIOL; ESTROGEN; HYDRALAZINE; ISOSORBIDE DINITRATE; METOPROLOL; PLACEBO; SEX HORMONE; SPIRONOLACTONE; TESTOSTERONE; VALSARTAN;

ADAPTIVE IMMUNITY; ADD ON THERAPY; ARTICLE; CARDIOVASCULAR DISEASE; CONGESTIVE CARDIOMYOPATHY; DRUG MEGADOSE; DRUG WITHDRAWAL; FEMALE; GENETIC VARIABILITY; HEART FAILURE; HEART LEFT VENTRICLE; HUMAN; IMMUNOPATHOLOGY; INJURY; INNATE IMMUNITY; LOW DRUG DOSE; MALE; MYOCARDITIS; NONHUMAN; PATHOGENESIS; PERIPARTUM CARDIOMYOPATHY; PROFESSIONAL KNOWLEDGE; PROGNOSIS; SEX DIFFERENCE; SURVIVAL; SYSTOLIC HEART FAILURE;

EID: 84869458989     PISSN: 01462806     EISSN: 15356280     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2012.07.003     Document Type: Article

References (176)

1. Lee L.V., Foody J.M. Women and heart disease. Cardiol Clin 2011, 29:35-45.
2. McNamara D.M., Starling R.C., Cooper L.T., et al. Clinical and demographic predictors of outcomes in recent onset dilated cardiomyopathy: results of the IMAC (Intervention in Myocarditis and Acute Cardiomyopathy)-2 study. J Am Coll Cardiol 2011, 58:1112-1118.
3. Regitz-Zagrosek V., Seeland U. Sex and gender differences in myocardial hypertrophy and heart failure. Wien Med Wochenschr 2011, 161:109-116.
4. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Executive summary: heart disease and stroke statistics-2012 update: a report from the American Heart Association. Circulation 2012, 125:188-197.
5. Woodruff J.F. Viral myocarditis. A review. Am J Pathol 1980, 101:425-484.
6. Cocker M.S., Abdel-Aty H., Strohm O., et al. Age and gender effects on the extent of myocardial involvement in acute myocarditis: a cardiovascular magnetic resonance study. Heart 2009, 95:1925-1930.
7. Cooper L.T., Mather P.J., Alexis J.D., et al. Myocardial recovery in peripartum cardiomyopathy: prospective comparison with recent onset cardiomyopathy in men and nonperipartum women. J Card Fail 2012, 18:28-33.
8. Lyden D.C., Olszewski J., Feran M., et al. Coxsackievirus B-3-induced myocarditis. Effect of sex steroids on viremia and infectivity of cardiocytes. Am J Pathol 1987, 126:432-438.
9. Ludden T.E., Edwards J.E. Carditis in poliomyelitis; an anatomic study of 35 cases and review of the literature. Am J Pathol 1949, 25:357-381.
10. Sainani G.S., Krompotic E., Slodki S.J. Adult heart disease due to the Coxsackie virus B infection. Medicine 1968, 47:133-147.
11. Frisancho-Kiss S., Davis S.E., Nyland J.F., et al. Cutting edge: cross-regulation by TLR4 and T cell Ig mucin-3 determines sex differences in inflammatory heart disease. J Immunol 2007, 178:6710-6714.
12. Huber S.A., Job L.P., Auld K.R. Influence of sex hormones on Coxsackie B-3 virus infection in Balb/c mice. Cell Immunol 1982, 67:173-179.
13. Exploring the Biological Contributions to Human Health: Does Sex Matter? 2001, Institute of Medicine, National Academies Press, Washington, DC.
14. Cleland J.G., Swedberg K., Follath F., et al. The EuroHeart Failure survey programme-a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J 2003, 24:442-463.
15. Luchner A., Bröckel U., Muscholl M., et al. Gender-specific differences of cardiac remodeling in subjects with left ventricular dysfunction: a population-based study. Cardiovasc Res 2002, 53:720-727.
16. Cooper L.T. Myocarditis. N Engl J Med 2009, 360:1526-1538.
17. Grzybowski J., Bilińska Z.T., Ruzyłło W., et al. Determinants of prognosis in nonischemic dilated cardiomopathy. J Card Fail 1996, 2:77-85.
18. Dec G.W., Fuster V. Idiopathic dilated cardiomyopathy. N Engl J Med 1994, 331:1564-1575.
19. Elliott P., Andersson B., Arbustini E., et al. Classification of the cardiomyopathies: a position statement from the European Society of Cardiology Working Group on myocardial and pericardial diseases. Eur Heart J 2008, 29:270-276.
20. Blauwet L.A., Cooper L.T. Myocarditis. Prog Cardiovasc Dis 2010, 52:274-288.
21. Sagar S., Liu P.P., Cooper L.T. Myocarditis. Lancet 2012, 379:738-747.
22. Friedrich M.G., Sechtem U., Schulz-Menger J., et al. Cardiovascular magnetic resonance in myocarditis: a JACC White Paper. J Am Coll Cardiol 2009, 53:1475-1487.
23. Pearson G.D., Veille J.C., Rahimtoola S., et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA 2000, 283:1183-1188.
24. Sliwa K., Hilfiker-Kleiner D., Petrie M.C., et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010, 12:767-778.
25. Mason J.W., O'Connell J.B., Herskowitz A., et al. A clinical trial of immunosuppressive therapy for myocarditis. The Myocarditis Treatment Trial Investigators. N Engl J Med 1995, 333:269-275.
26. Caforio A.L., Calabrese F., Angelini A., et al. A prospective study of biopsy-proven myocarditis: prognostic relevance of clinical and aetiopathogenetic features at diagnosis. Eur Heart J 2007, 28:1326-1333.
27. Magnani J.W., Danik H.J., Dec G.W., et al. Survival in biopsy-proven myocarditis: a long-term retrospective analysis of the histopathologic, clinical, and hemodynamic predictors. Am Heart J 2006, 151:463-470.
28. Bagger J.P., Baandrup U., Rasmussen K., et al. Cardiomyopathy in western Denmark. Br Heart J 1984, 52:327-331.
29. Gillum R.F. Idiopathic cardiomyopathy in the United States, 1970-1982. Am Heart J 1986, 111:752-755.
30. Coughlin S.S., Comstock G.W., Baughman K.L. Descriptive epidemiology of idiopathic dilated cardiomyopathy in Washington County, Maryland, 1975-1991. J Clin Epidemiol 1993, 46:1003-1008.
31. Codd M.B., Sugrue D.D., Gersh B.J., et al. Epidemiology of idiopathic dilated and hypertrophic cardiomyopathy. A population-based study in Olmsted County, Minnesota, 1975-1984. Circulation 1989, 80:564-572.
32. Agüero J., Navarro J., Medina M.C., et al. Clinical variables associated with the presence of inflammatory infiltrates in patients with dilated cardiomyopathy undergoing heart transplantation. Transplant Proc 2008, 40:3017-3019.
33. Blauwet L.A., Cooper L.T. Diagnosis and management of peripartum cardiomyopathy. Heart 2011, 97:1970-1981.
34. Stefanelli C.B., Rosenthal A., Borisov A.B., et al. Novel troponin T mutation in familial dilated cardiomyopathy with gender-dependant severity. Mol Genet Metab 2004, 83:188-196.
35. Haddad G.E., Saunders L.J., Crosby S.D., et al. Human cardiac-specific cDNA array for idiopathic dilated cardiomyopathy: sex-related differences. Physiol Genomics 2008, 33:267-277.
36. Herman D.S., Lam L., Taylor M.R., et al. Truncations of titin causing dilated cardiomyopathy. N Engl J Med 2012, 366:619-628.
37. Massad L.S., Reiss C.K., Mutch D.G., et al. Familial peripartum cardiomyopathy after molar pregnancy. Obstet Gynecol 1993, 81:886-888.
38. Pearl W. Familial occurrence of peripartum cardiomyopathy. Am Heart J 1995, 129:421-422.
39. Fett J.D., Sundstrom B.J., Etta King M., et al. Mother-daughter peripartum cardiomyopathy. Int J Cardiol 2002, 86:331-332.
40. Pierce J.A., Price B.O., Joyce J.W. Familial occurrence of postpartal heart failure. Arch Intern Med 1963, 111:651-655.
41. van Spaendonck-Zwarts K.Y., van Tintelen J.P., van Veldhuisen D.J., et al. Peripartum cardiomyopathy as a part of familial dilated cardiomyopathy. Circulation 2010, 121:2169-2175.
42. Morales A., Painter T., Li R., et al. Rare variant mutations in pregnancy-associated or peripartum cardiomyopathy. Circulation 2010, 121:2176-2182.
43. Horne B.D., Rasmusson K.D., Alharethi R., et al. Genome-wide significance and replication of the chromosome 12p11.22 locus near the PTHLH gene for peripartum cardiomyopathy. Circ Cardiovasc Genet 2011, 4:359-366.
44. Isensee J., Witt H., Pregla R., et al. Sexually dimorphic gene expression in the heart of mice and men. J Mol Med (Berl) 2008, 86:61-74.
45. Heidecker B., Lamirault G., Kasper E.K., et al. The gene expression profile of patients with new-onset heart failure reveals important gender-specific differences. Eur Heart J 2010, 31:1188-1196.
46. Salton C.J., Chuang M.L., O'Donnell C.J., et al. Gender differences and normal left ventricular anatomy in an adult population free of hypertension. A cardiovascular magnetic resonance study of the Framingham Heart Study Offspring cohort. J Am Coll Cardiol 2002, 39:1055-1060.
47. de Simone G., Devereux R.B., Daniels S.R., et al. Gender differences in left ventricular growth. Hypertension 1995, 26:979-983.
48. Melchert R.B., Kennedy R.H., Acosta D. Cardiovascular effects of steroidal agents. Cardiovascular Toxicology 2001, 425-475. Taylor & Francis, London. D. Acosta (Ed.).
49. Scheuer J., Malhotra A., Schaible T.F., et al. Effects of gonadectomy and hormonal replacement on rat hearts. Circ Res 1987, 61:12-19.
50. Mallat Z., Fornes P., Costagliola R., et al. Age and gender effects on cardiomyocyte apoptosis in the normal human heart. J Gerontol A Biol Sci Med Sci 2001, 56:M719-M723.
51. Sheppard R., Bedi M., Kubota T., et al. Myocardial expression of Fas and recovery of left ventricular function in patients with recent-onset cardiomyopathy. J Am Coll Cardiol 2005, 46:1036-1042.
52. Deslypere J.P., Vermeulen A. Influence of age on steroid concentrations in skin and striated muscle in women and in cardiac muscle and lung tissue in men. J Clin Endocrinol Metab 1985, 61:648-653.
53. Robinson D.P., Huber S.A., Moussawi M., et al. Sex chromosome complement contributes to sex differences in coxsackievirus B3 but not influenza A virus pathogenesis. Biol Sex Differ 2011, 2:8.
54. Frisancho-Kiss S., Nyland J.F., Davis S.E., et al. Sex differences in coxsackievirus B3-induced myocarditis: IL-12Rβ1 signaling and IFN-γ increase inflammation in males independent from STAT4. Brain Res 2006, 1126:139-147.
55. Coronado M.J., Brandt J.E., Kim E., et al. Testosterone and interleukin-1β increase cardiac remodeling during acute coxsackievirus B3 myocarditis via serpin A 3n. Am J Physiol Heart Circ Physiol 2012, 302:H1726-H1736.
56. Vitale C., Mendelsohn M.E., Rosano G.M. Gender differences in the cardiovascular effect of sex hormones. Nat Rev Cardiol 2009, 6:532-542.
57. McCrohon J.A., Death A.K., Nakhla S., et al. Androgen receptor expression is greater in macrophages from male than from female donors. A sex difference with implications for atherogenesis. Circulation 2000, 101:224-226.
58. Fairweather D., Yusung S., Frisancho S., et al. IL-12Rβ1 and TLR4 increase IL-1β and IL-18-associated myocarditis and coxsackievirus replication. J Immunol 2003, 170:4731-4737.
59. Satoh M., Nakamura M., Akatsu T., et al. Expression of Toll-like receptor 4 is associated with enteroviral replication in human myocarditis. Clin Sci 2003, 104:577-584.
60. Satoh M., Nakamura M., Akatsu T., et al. Toll-like receptor 4 is expressed with enteroviral replication in myocardium from patients with dilated cardiomyopathy. Lab Invest 2004, 84:173-181.
61. Lahita R.G. Sex hormones and immune function. Principles of Gender-Specific Medicine 2010, 615-626. Elsevier, Burlington, MA. 2nd ed. M.J. Legato (Ed.).
62. Girón-González J.A., Moral F.J., Elvira J., et al. Consistent production of a higher TH1:TH2 cytokine ratio by stimulated T cells in men compared with women. Eur J Endocrinol 2000, 143:31-36.
63. Huber S.A. Coxsackievirus B3-induced myocarditis: infection of females during the estrus phase of the ovarian cycle leads to activation of T regulatory cells. Virology 2008, 378:292-298.
64. Huber S.A., Pfaeffle B. Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3. J Virol 1994, 68:5126-5132.
65. Huber S.A. Increased susceptibility of male BALB/c mice to coxsackievirus B3-induced myocarditis: role for CD1d. Med Microbiol Immunol 2005, 194:121-127.
66. + T cells, Th2 cells and Treg in the heart during acute coxsackievirus-induced myocarditis. Brain Behav Immun 2009, 23:649-657.
67. + Th2 cells by altering Bcl2 expression. Lupus 1999, 8:384-387.
68. Warraich R.S., Noutsias M., Kazac I., et al. Immunoglobulin G3 cardiac myosin autoantibodies correlate with left ventricular dysfunction in patients with dilated cardiomyopathy: immunoglobulin G3 and clinical correlates. Am Heart J 2002, 143:1076-1084.
69. Asakura M., Kitakaze M. Global gene expression profiling in the failing myocardium. Circ J 2009, 73:1568-1576.
70. Cavasin M.A., Tao Z.Y., Yu A.L., et al. Testosterone enhances early cardiac remodeling after myocardial infarction, causing rupture and degrading cardiac function. Am J Physiol Heart Circ Physiol 2006, 290:H2043-H2050.
71. 1, IL-1β, and IL-4 in the heart. Am J Pathol 2004, 165:1883-1894.
72. Boheler K.R., Volkova M., Morrell C., et al. Sex- and age-dependent human transcriptome variability: implications for chronic heart failure. Proc Natl Acad Sci USA 2003, 100:2754-2759.
73. Barsheshet A., Brenyo A., Goldenberg I., et al. Sex-related differences in patients' responses to heart failure therapy. Nat Rev Cardiol 2012, 9:234-242.
74. Lenzen M.J., Rosengren A., Scholte op Reimer W.J., et al. Management of patients with heart failure in clinical practice: differences between men and women. Heart 2008, 94:e10.
75. Onyimba J.A., Coronado M.J., Garton A.E., et al. The innate immune response to coxsackievirus B3 predicts progression to cardiovascular disease and heart failure in male mice. Biol Sex Differ 2011, 2:2.
76. Basaria S., Coviello A.D., Travison T.G., et al. Adverse events associated with testosterone administration. N Engl J Med 2010, 363:109-122.
77. Chung A.K., Das S.R., Leonard D., et al. Women have higher left ventricular ejection fractions than men independent of differences in left ventricular volume: the Dallas Heart Study. Circulation 2006, 113:1597-1604.
78. Merz C.N., Moriel M., Rozanski A., et al. Gender-related differences in exercise ventricular function among healthy subjects and patients. Am Heart J 1996, 131:704-709.
79. Olivetti G., Giordano G., Corradi D., et al. Gender differences and aging: effects on the human heart. J Am Coll Cardiol 1995, 26:1068-1079.
80. Dannenberg A.L., Levy D., Garrison R.J. Impact of age on echocardiographic left ventricular mass in a healthy population (the Framingham study). Am J Cardiol 1989, 64:1066-1068.
81. Kim S.G., Apple S., Mintz G.S., et al. The importance of gender on coronary artery size: in-vivo assessment by intravascular ultrasound. Clin Cardiol 2004, 27:291-294.
82. Burt V.L., Whelton P., Roccella E.J., et al. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension 1995, 25:305-313.
83. Stamler J., Stamler R., Riedlinger W.F., et al. Hypertension screening of 1 million Americans. Community Hypertension Evaluation Clinic (CHEC) program, 1973 through 1975. JAMA 1976, 235:2299-2306.
84. Bazett H.C. The time relations of the blood-pressure changes after excision of the adrenal glands, with some observations on blood volume changes. J Physiol 1920, 53:320-339.
85. Isensee J., Ruiz Noppinger P. Sexually dimorphic gene expression in mammalian somatic tissue. Gend Med 2007, 4(suppl B):S75-S95.
86. Regitz-Zagrosek V., Becher E., Mahmoodzadeh S., et al. Sex steroid hormones. Cardiovascular hormone systems: from molecular mechanisms to novel therapeutics 2008, 39-64. Wiley-Blackwell, Weinheim, Germany. M. Bader (Ed.).
87. Fairweather D., Petri M.A., Coronado M.J., et al. Autoimmune heart disease: role of sex hormones and autoantibodies in disease pathogenesis. Expert Rev Clin Immunol 2012, 8:269-284.
88. Sliwa K., Förster O., Libhaber E., et al. Peripartum cardiomyopathy: inflammatory markers as predictors of outcome in 100 prospectively studied patients. Eur Heart J 2006, 27:441-446.
89. Sliwa K., Skudicky D., Bergemann A., et al. Peripartum cardiomyopathy: analysis of clinical outcome, left ventricular function, plasma levels of cytokines and Fas/APO-1. J Am Coll Cardiol 2000, 35:701-705.
90. Bursi F., Weston S.A., Redfield M.M., et al. Systolic and diastolic heart failure in the community. JAMA 2006, 296:2209-2216.
91. Robinson T., Smith A., Channer K.S. Reversible heart failure: the role of inflammatory activation. Postgrad Med J 2011, 87:110-115.
92. Gilliver S.C. Sex steroids as inflammatory regulators. J Steroid Biochem Mol Biol 2010, 120:105-115.
93. Villablanca A.C., Jayachandran M., Banka C. Atherosclerosis and sex hormones: current concepts. Clin Sci 2010, 119:493-513.
94. Hammes S.R., Levin E.R. Minireview: recent advances in extranuclear steroid receptor actions. Endocrinology 2011, 152:4489-4495.
95. Hodgin J.B., Krege J.H., Reddick R.L., et al. Estrogen receptor alpha is a major mediator of 17beta-estradiol's atheroprotective effects on lesion size in Apoe-/- mice. J Clin Invest 2001, 107:333-340.
96. Cook I.F. Sexual dimorphism of humoral immunity with human vaccines. Vaccine 2008, 26:3551-3555.
97. Fairweather D., Frisancho-Kiss S., Rose N.R. Sex differences in autoimmune disease from a pathological perspective. Am J Pathol 2008, 173:600-609.
98. Papenfuss T.L., Powell N.D., McClain M.A., et al. Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity. J Immunol 2011, 186:3346-3355.
99. Rubtsov A.V., Rubtsova K., Kappler J.W., et al. Genetic and hormonal factors in female-biased autoimmunity. Autoimmun Rev 2010, 9:494-498.
100. Straub R.H. The complex role of estrogens in inflammation. Endocr Rev 2007, 28:521-574.
101. Deshpande R., Khalili H., Pergolizzi R.G., et al. Estradiol down-regulates LPS-induced cytokine production and NFκB activation in murine macrophages. Am J Reprod Immunol 1997, 38:46-54.
102. Evans M.J., Eckert A., Lai K., et al. Reciprocal antagonism between estrogen receptor and NF-kappaB activity in vivo. Circ Res 2001, 89:823-830.
103. Temple S.E., Pham K., Glendenning P., et al. Endotoxin induced TNF and IL-10 mRNA production is higher in male than female donors: correlation with elevated expression of TLR4. Cell Immunol 2008, 251:69-71.
104. Saha Roy S., Vadlamudi R.K. Role of estrogen receptor signaling in breast cancer metastasis. Int J Breast Cancer 2012, 2012:654698.
105. Miller V.M. In pursuit of scientific excellence: sex matters. Am J Physiol Heart Circ Physiol 2012, 302:H1771-H1772.
106. Cutolo M., Brizzolara R., Atzeni F., et al. The immunomodulatory effects of estrogens: clinical relevance in immune-mediated rheumatic diseases. Ann N Y Acad Sci 2010, 1193:36-42.
107. Blauwet L.A., Hayes S.N., McManus D., et al. Low rate of sex-specific result reporting in cardiovascular trials. Mayo Clin Proc 2007, 82:166-170.
108. Sex-specific Reporting of Scientific Research: A Workshop Summary 2012, 1-59. The Institute of Medicine of the National Academies, The National Academies Press, Washington, DC. http://www.national-academies.org.
109. Li K., Xu W., Guo Q., et al. Differential macrophage polarization in male and female BALB/c mice infected with coxsackievirus B3 defines susceptibility to viral myocarditis. Circ Res 2009, 105:353-364.
110. Fairweather D., Frisancho-Kiss S. Mast cells and inflammatory heart disease: potential drug targets. Cardiovasc Hematol Disord Drug Targets 2008, 8:80-90.
111. Levick S.P., Meléndez G.C., Plante E., et al. Cardiac mast cells: the centrepiece in adverse myocardial remodelling. Cardiovasc Res 2011, 89:12-19.
112. Kania G., Blyszczuk P., Eriksson U. Mechanisms of cardiac fibrosis in inflammatory heart disease. Trends Cardiovasc Med 2009, 19:247-252.
113. Abston E.D., Coronado M.J., Bucek A., et al. Th2 regulation of viral myocarditis in mice: different roles for TLR3 vs. TRIF in progression to chronic disease. Clin Dev Immunol 2012, 2012:129486.
114. Fairweather D., Rose N.R. Coxsackievirus-induced myocarditis in mice: a model of autoimmune disease for studying immunotoxicity. Methods 2007, 41:118-122.
115. Abston E.D., Barin J.G., Cihakova D., et al. IL-33 independently induces eosinophilic pericarditis and cardiac dilation: ST2 improves cardiac function. Circ Heart Fail 2012, 5:366-375.
116. Jones T.H. Testosterone deficiency: a risk factor for cardiovascular disease?. Trends Endocrinol Metab 2010, 21:496-503.
117. Malkin C.J., Pugh P.J., Morris P.D., et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010, 96:1821-1825.
118. Yeap B.B. Androgens and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 2010, 17:269-276.
119. Ohlsson C., Barrett-Connor E., Bhasin S., et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden. J Am Coll Cardiol 2011, 58:1674-1681.
120. Hales D.B. Interleukin-1 inhibits Leydig cell steroidogenesis primarily by decreasing 17 alpha-hydroxylase/C17-20 lyase cytochrome P450 expression. Endocrinology 1992, 131:2165-2172.
121. Johnstone D., Limacher M., Rousseau M., et al. Clinical characteristics of patients in studies of left ventricular dysfunction (SOLVD). Am J Cardiol 1992, 70:894-900.
122. De Maria R., Gavazzi A., Recalcati F., et al. Comparison of clinical findings in idiopathic dilated cardiomyopathy in women versus men. The Italian Multicenter Cardiomyopathy Study Group (SPIC). Am J Cardiol 1993, 72:580-585.
123. Goland S., Modi K., Bitar F., et al. Clinical profile and predictors of complications in peripartum cardiomyopathy. J Card Fail 2009, 15:645-650.
124. Chin M.H., Goldman L. Gender differences in 1-year survival and quality of life among patients admitted with congestive heart failure. Med Care 1998, 36:1033-1046.
125. Riedinger M.S., Dracup K.A., Brecht M.L., et al. Quality of life in patients with heart failure: do gender differences exist?. Heart Lung 2001, 30:105-116.
126. Azevedo A., Bettencourt P., Pimenta J., et al. Clinical syndrome suggestive of heart failure is frequently attributable to non-cardiac disorders-population-based study. Eur J Heart Fail 2007, 9:391-396.
127. O'Meara E., Clayton T., McEntegart M.B., et al. Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation 2007, 115:3111-3120.
128. Baumhäkel M., Müller U., Böhm M. Influence of gender of physicians and patients on guideline-recommended treatment of chronic heart failure in a cross-sectional study. Eur J Heart Fail 2009, 11:299-303.
129. Klein L., Grau-Sepulveda M.V., Bonow R.O., et al. Quality of care and outcomes in women hospitalized for heart failure. Circ Heart Fail 2011, 4:589-598.
130. Simon T., Mary-Krause M., Funck-Brentano C., et al. Sex differences in the prognosis of congestive heart failure: results from the Cardiac Insufficiency Bisoprolol Study (CIBIS II). Circulation 2001, 103:375-380.
131. Ghali J.K., Krause-Steinrauf H.J., Adams K.F., et al. Gender differences in advanced heart failure: insights from the BEST study. J Am Coll Cardiol 2003, 42:2128-2134.
132. Ghali J.K., Piña I.L., Gottlieb S.S., et al. Metoprolol CR/XL in female patients with heart failure: analysis of the experience in Metoprolol Extended-Release Randomized Intervention Trial in Heart Failure (MERIT-HF). Circulation 2002, 105:1585-1591.
133. Packer M., Bristow M.R., Cohn J.N., et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996, 334:1349-1355.
134. Packer M., Coats A.J., Fowler M.B., et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001, 344:1651-1658.
135. Garg R., Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995, 273:1450-1456.
136. Shekelle P.G., Rich M.W., Morton S.C., et al. Efficacy of angiotensin-converting enzyme inhibitors and beta-blockers in the management of left ventricular systolic dysfunction according to race, gender, and diabetic status: a meta-analysis of major clinical trials. J Am Coll Cardiol 2003, 41:1529-1538.
137. Young J.B., Dunlap M.E., Pfeffer M.A., et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation 2004, 110:2618-2626.
138. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001, 345:1667-1675. Valsartan Heart Failure Trial Investigators.
139. Pitt B., Zannad F., Remme W.J., et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999, 341:709-717.
140. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
141. Zannad F., McMurray J.J., Krum H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011, 364:11-21.
142. Taylor A.L., Ziesche S., Yancy C., et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004, 351:2049-2057.
143. Taylor A.L., Lindenfeld J., Ziesche S., et al. Outcomes by gender in the African-American Heart Failure Trial. J Am Coll Cardiol 2006, 48:2263-2267.
144. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997, 336:525-533. The Digitalis Investigation Group.
145. Rathore S.S., Wang Y., Krumholz H.M. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med 2002, 347:1403-1411.
146. Rathore S.S., Curtis J.P., Wang Y., et al. Association of serum digoxin concentration and outcomes in patients with heart failure. JAMA 2003, 289:871-878.
147. Hsich E.M., Piña I.L. Heart failure in women: a need for prospective data. J Am Coll Cardiol 2009, 54:491-498.
148. Hilfiker-Kleiner D., Kaminski K., Podewski E., et al. A cathepsin D-cleaved 16 kDa form of prolactin mediates postpartum cardiomyopathy. Cell 2007, 128:589-600.
149. Sliwa K., Blauwet L., Tibazarwa K., et al. Evaluation of bromocriptine in the treatment of acute severe peripartum cardiomyopathy: a proof-of-concept pilot study. Circulation 2010, 121:1465-1473.
150. Cohn J.N., Archibald D.G., Ziesche S., et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986, 314:1547-1552.
151. Cohn J.N., Johnson G., Ziesche S., et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991, 325:303-310.
152. Alaeddini J., Wood M.A., Amin M.S., et al. Gender disparity in the use of cardiac resynchronization therapy in the United States. Pacing Clin Electrophysiol 2008, 31:468-472.
153. Curtis L.H., Al-Khatib S.M., Shea A.M., et al. Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. JAMA 2007, 298:1517-1524.
154. Santangeli P., Pelargonio G., Dello Russo A., et al. Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: a systematic review and meta-analysis. Heart Rhythm 2010, 7:876-882.
155. Ghanbari H., Dalloul G., Hasan R., et al. Effectiveness of implantable cardioverter-defibrillators for the primary prevention of sudden cardiac death in women with advanced heart failure: a meta-analysis of randomized controlled trials. Arch Intern Med 2009, 169:1500-1506.
156. Kadish A., Dyer A., Daubert J.P., et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med 2004, 350:2151-2158.
157. Albert C.M., Quigg R., Saba S., et al. Sex differences in outcome after implantable cardioverter defibrillator implantation in nonischemic cardiomyopathy. Am Heart J 2008, 156:367-372.
158. Hernandez A.F., Fonarow G.C., Liang L., et al. Sex and racial differences in the use of implantable cardioverter-defibrillators among patients hospitalized with heart failure. JAMA 2007, 298:1525-1532.
159. Al-Khatib S.M., Hellkamp A.S., Hernandez A.F., et al. Trends in use of implantable cardioverter-defibrillator therapy among patients hospitalized for heart failure: have the previously observed sex and racial disparities changed over time?. Circulation 2012, 125:1094-1101.
160. McAlister F.A., Ezekowitz J.A., Wiebe N., et al. Systematic review: cardiac resynchronization in patients with symptomatic heart failure. Ann Intern Med 2004, 141:381-390.
161. Goldenberg I., Moss A.J., Hall W.J., et al. Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 2011, 124:1527-1536.
162. van Bommel R.J., Bax J.J., Abraham W.T., et al. Characteristics of heart failure patients associated with good and poor response to cardiac resynchronization therapy: a PROSPECT (Predictors of Response to CRT) sub-analysis. Eur Heart J 2009, 30:2470-2477.
163. Stabile G., Solimene F., Bertaglia E., et al. Long-term outcomes of CRT-PM versus CRT-D recipients. Pacing Clin Electrophysiol 2009, 32(suppl 1):S141-S145.
164. Mooyaart E.A., Marsan N.A., van Bommel R.J., et al. Comparison of long-term survival of men versus women with heart failure treated with cardiac resynchronization therapy. Am J Cardiol 2011, 108:63-68.
165. Topkara V.K., Dang N.C., Barili F., et al. Ventricular assist device use for the treatment of acute viral myocarditis. J Thorac Cardiovasc Surg 2006, 131:1190-1191.
166. Bogaev R.C., Pamboukian S.V., Moore S.A., et al. Comparison of outcomes in women versus men using a continuous-flow left ventricular assist device as a bridge to transplantation. J Heart Lung Transplant 2011, 30:515-522.
167. Murray L.K., González-Costello J., Jonas S.N., et al. Ventricular assist device support as a bridge to heart transplantation in patients with giant cell myocarditis. Eur J Heart Fail 2012, 14:312-318.
168. Stehlik J., Edwards L.B., Kucheryavaya A.Y., et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-eighth Adult Heart Transplant Report-2011. J Heart Lung Transplant 2011, 30:1078-1094.
169. Regitz-Zagrosek V., Petrov G., Lehmkuhl E., et al. Heart transplantation in women with dilated cardiomyopathy. Transplantation 2010, 89:236-244.
170. Aaronson K.D., Schwartz J.S., Goin J.E., et al. Sex differences in patient acceptance of cardiac transplant candidacy. Circulation 1995, 91:2753-2761.
171. Rasmusson K., Brunisholz K., Budge D., et al. Peripartum cardiomyopathy: post-transplant outcomes from the United Network for Organ Sharing Database. J Heart Lung Transplant 2012, 31:180-186.
172. Gleicher N., Elkayam U. Perpartum cardiomyopathy, an autoimmune manifestation of allorgraft rejection?. Autoimmun Rev 2009, 8:384-387.
173. Amarelli C., De Santo L.S., Marra C., et al. Early graft failure after heart transplant: risk factors and implications for improved donor-recipient matching. Interact Cardiovasc Thorac Surg 2012, 15:57-62.
174. Ho K.K., Anderson K.M., Kannel W.B., et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993, 88:107-115.
175. Kadokami T., McTiernan C.F., Kubota T., et al. Sex-related survival differences in murine cardiomyopathy are associated with differences in TNF-receptor expression. J Clin Invest 2000, 105:589-597.
176. Simon M.A., Primack B.A., Teuteberg J., et al. Left ventricular remodeling and myocardial recovery on mechanical circulatory support. Card Fail 2010, 16:99-105.